3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a Novel Adenosine Receptor Antagonist with A2A-Mediated Neuroprotective EffectsClick to copy article linkArticle link copied!
- Alessia Scatena
- Francesco Fornai
- Maria Letizia Trincavelli
- Sabrina Taliani
- Simona Daniele
- Isabella Pugliesi
- Sandro Cosconati
- Claudia Martini
- Federico Da Settimo
Abstract
In this study, compound FTBI (3-(2-furyl)-10-(2-phenylethyl)[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one) was selected from a small library of triazinobenzimidazole derivatives as a potent A2A adenosine receptor (AR) antagonist and tested for its neuroprotective effects against two different kinds of dopaminergic neurotoxins, 1-methyl-4-phenylpyridinium (MPP+) and methamphetamine (METH), in rat PC12 and in human neuroblastoma SH-SY5Y cell lines. FTBI, in a concentration range corresponding to its affinity for A2A AR subtype, significantly increased the number of viable PC12 cells after their exposure to METH and, to a similar extent, to MPP+, as demonstrated in both trypan blue exclusion assay and in cytological staining. These neuroprotective effects were also observed with a classical A2A AR antagonist, ZM241385, and appeared to be completely counteracted by the AR agonist, NECA, supporting A2A ARs are directly involved in FTBI-mediated effects. Similarly, in human SH-SY5Y cells, FTBI was able to prevent cell toxicity induced by MPP+ and METH, showing that this A2A AR antagonist has a neuroprotective effect independently by the specific cell model. Altogether these results demonstrate that the A2A AR blockade mediates cell protection against neurotoxicity induced by dopaminergic neurotoxins in dopamine containing cells, supporting the potential use of A2A AR antagonists in dopaminergic degenerative diseases including Parkinson’s disease.
Cited By
This article is cited by 7 publications.
- Matteo Falsini, Lucia Squarcialupi, Daniela Catarzi, Flavia Varano, Marco Betti, Diego Dal Ben, Gabriella Marucci, Michela Buccioni, Rosaria Volpini, Teresa De Vita, Andrea Cavalli, and Vittoria Colotta . The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype. Journal of Medicinal Chemistry 2017, 60
(13)
, 5772-5790. https://doi.org/10.1021/acs.jmedchem.7b00457
- Ana Carla L. Nunes, Marta Carmo, Andrea Behrenswerth, Paula M. Canas, Paula Agostinho, Rodrigo A. Cunha. Adenosine A2A Receptor Blockade Provides More Effective Benefits at the Onset Rather than after Overt Neurodegeneration in a Rat Model of Parkinson’s Disease. International Journal of Molecular Sciences 2024, 25
(9)
, 4903. https://doi.org/10.3390/ijms25094903
- Huiying Wang, Yitian Ma, Xiaochen Wang, Wenpei Zhang, Wei Han, Haobiao Liu, Miao Li, Jing Xiao, Hang Wei, Changqing Wang, Shria Sindhwani, Tianxiao Zhang, Fanglin Guan, John P. Rice. Evaluation of Adenosine A2A receptor gene polymorphisms as risk factors of methamphetamine use disorder susceptibility and predictors of craving degree. Psychiatry Research 2022, 316 , 114790. https://doi.org/10.1016/j.psychres.2022.114790
- Olivier R.P. David. Bicyclic 5-6 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: Three Extra Heteroatoms 1:2. 2022, 755-779. https://doi.org/10.1016/B978-0-12-818655-8.00058-5
- Egor K. Voinkov, Roman A. Drokin, Evgeny N. Ulomsky, Oleg N. Chupakhin, Valery N. Charushin, Vladimir L. Rusinov. Methods of Synthesis for the Azolo[1,2,4]Triazines. Chemistry of Heterocyclic Compounds 2020, 56
(10)
, 1254-1273. https://doi.org/10.1007/s10593-020-02808-z
- Elisabetta Barresi, Chiara Giacomelli, Simona Daniele, Ilaria Tonazzini, Marco Robello, Silvia Salerno, Ilaria Piano, Barbara Cosimelli, Giovanni Greco, Federico Da Settimo, Claudia Martini, Maria Letizia Trincavelli, Sabrina Taliani. Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes. Bioorganic & Medicinal Chemistry 2018, 26
(22)
, 5885-5895. https://doi.org/10.1016/j.bmc.2018.10.039
- Rachit Bakshi, Robert Logan, Michael A. Schwarzschild. Purines in Parkinson’s: Adenosine A2A Receptors and Urate as Targets for Neuroprotection. 2015, 101-126. https://doi.org/10.1007/978-3-319-20273-0_6
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.
Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.
The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated.